Coriolis Pharma, a globally operating service provider and one of the world leaders in formulation research and development of bio-pharmaceutical drugs, will collaborate with RheaVita in an effort to pave the way for drug development of biologics using RheaVita’s novel single vial unit (SVU) technology for continuous and controlled freeze-drying technology, particularly to stabilize novel […]
• Novel non-viral gene delivery platform to help advance tissue repair following orthopaedic surgery • Funding from Innovate UK’s Transforming Medicines Manufacturing programme supporting innovative technologies for intracellular drug delivery
AntlerA Norrin/Wnt-agonist antibody, through a strategic partnership with EyeBio, has entered clinical trials for treatment of retinopathies.
Genomic Vision, a Euronext-listed biotechnology company that develops products and services for the characterization of DNA sequences, has secured an exclusive European distribution agreement with CliniSciences.
GBA Group, a leading European life science service provider, has entered the U.S. market with a site in Westborough, Massachusetts to support clinical trials. Located in the greater Boston area, a pharmaceutical and biotech hub, the laboratory and logistics site will be fully operational in October this year and will offer a broad range of […]
Appointment part of company’s ambitious global growth strategy CN Bio, one of the world’s leading Organ-on-a-Chip companies has appointed Dr Samantha Macro as Chief Financial Officer. Dr Macro joins CEO, Dr Paul Brooks, on the executive board to guide key commercial and strategic initiatives, increase revenue and shape the company’s growth trajectory.
Avacta Group has acquired Coris Bioconcept for £7.4 million and an extra £3 million payout based on future business performance.
Scientists have taken an important step forward in predicting who will develop Type 1 diabetes months before symptoms appear.
A study of more than 22,000 people with multiple sclerosis has discovered the first genetic variant associated with faster disease progression, which can rob patients of their mobility and independence over time.
Synexa Life Sciences, a specialist biomarker and bioanalysis service provider, has joined the Coalition for Epidemic Preparedness Innovations (CEPI) Central Lab Network (CLN). The company says the strategic partnership represents a significant milestone in its commitment to global health security and its dedication to fostering collaboration and innovation in epidemic preparedness and response.
May 2026
Prins Hendrikstraat 1
5611HH Eindhoven
The Netherlands
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.